1.12 USD
▲-0.05+5.66%
盘后 1.06 +0.39%
2026-08-03
市值
$26.80M
市盈率
—
EPS
-0.98
股息率
—
52 周区间
1.03 – 9.22
成交量
309.75K
Beta
—
目标价
9.98
52W 低 1.0352W 高 9.22
价格走势
公司简介
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apothe...